

August 9, 2022

Company: FINDEX Inc  
Representative: Teruo Aibara, President & CEO  
(Stock code: 3649, TSE Prime)  
Contact: Atsushi Fujita  
Director and Head of Administration  
(TEL: +81-89-947-3388)

**[Correction] Notice of partial corrections**  
**to the Consolidated Financial Results [Japanese GAAP]**  
**for the First Quarter of the Fiscal Year Ending December 31, 2022**

We have found that corrections are required to certain items stated in the Consolidated Financial Results [Japanese GAAP] for the First Quarter of the Fiscal Year Ending December 31, 2022, which was disclosed on May 12th, 2022. The followings below are details of corrections.

**1. Reason for corrections**

After having filed the Consolidated Financial Results [Japanese GAAP] for the First Quarter of the Fiscal Year Ending December 31, 2022, we discovered partial error in stated items. This notice is retrospectively to correct those items.

**2. Items to be corrected**

Items to be retrospectively corrected are underlined as below.

**[Before correction]**

2. Quarterly Financial Statements and Notes  
(3) Notes to Quarterly Consolidated Financial Statement  
(Revenue Recognition)

The Group's revenues are primarily derived from revenues recognized from contracts with customers, and the following information breaks down the Group's reportable segments by the timing of revenue recognition and types of services.

FY 2022 1Q (From January 1, 2022, to March 31, 2022)

(JPY in Thousands)

	Reportable segment		Total
	System development	Healthtech	
Timing of revenue recognition			
Revenue recognized at a point in time	<u>861,224</u>	43,397	<u>904,622</u>
Revenue recognized over a period of time	<u>359,953</u>	-	<u>359,953</u>
Total	1,221,178	43,397	1,264,576

**[After correction]**

2. Quarterly Financial Statements and Notes

(3) Notes to Quarterly Consolidated Financial Statement

(Revenue Recognition)

The Group's revenues are primarily derived from revenues recognized from contracts with customers, and the following information breaks down the Group's reportable segments by the timing of revenue recognition and types of services.

FY 2022 1Q (From January 1, 2022, to March 31, 2022)

(JPY in Thousands)

	Reportable segment		Total
	System development	Healthtech	
Timing of revenue recognition			
Revenue recognized at a point in time	<u>598,682</u>	43,397	<u>642,080</u>
Revenue recognized over a period of time	<u>622,495</u>	-	<u>622,495</u>
Total	1,221,178	43,397	1,264,576